General endocrinology

Last updated: September 14, 2022

Summarytoggle arrow icon

Endocrinology is the study of the endocrine system (i.e., the hypothalamus, pituitary gland, thyroid gland, adrenals, and gonads), metabolic diseases, and certain aspects of nutritional medicine. The endocrine glands are responsible for producing and secreting hormones, which influence the function of cells in certain tissues of the body. Hormone secretion is controlled by highly regulated pathways, the most important of which is the hypothalamic-pituitary axis. The hypothalamus secretes and stores nontropic hormones (e.g., ADH, oxytocin) and releasing hormones (e.g., TRH, CRH, GnRH). The pituitary gland is composed of the anterior pituitary, which secretes tropic hormones (e.g., ACTH, TSH, FSH, LH) and whose function is controlled by hypothalamic releasing hormones, and the posterior pituitary, which stores ADH and oxytocin. The gonads are the ovaries in female individuals and testicles in male individuals. Their function is controlled via the hypothalamic-pituitary-gonadal axis, as well as the secretion of sex hormone-binding globulin (SHBG). Disruption of the hypothalamic-pituitary axis can result in the development of various endocrine disorders, which are classified according to the level of pathway disruption: primary (disorders of the peripheral endocrine gland), secondary (pituitary dysfunctions), and tertiary (hypothalamic disorders). An understanding of these hormone pathways is important for the diagnosis and management of endocrine disorders, particularly when interpreting changes in hormone levels and the results of suppression and/or stimulation tests.

For more information, see the articles "Thyroid gland and parathyroid glands" and “Adrenal gland.”

Overview of endocrinological diseasestoggle arrow icon

This article focuses on the hypothalamic-pituitary axis. Other important structures, hormones, and metabolic diseases are discussed in their respective articles.

Basics of endocrinologytoggle arrow icon


Overview of the most important types of hormones
Type of hormone Description Example
Based on signaling pathways
Paracrine hormones
Autocrine hormones
  • Affect the secreting cell itself
Endocrine hormones
  • Secreted into the bloodstream to reach their targets
Based on chemical nature
Steroid hormones
Amine hormones
Peptide hormones
Based on solubility
Lipophilic hormones
Hydrophilic hormones

Hydrophilic hormones (e.g., catecholamines) are stored in secretory granules and released when needed. Lipophilic hormones (e.g., adrenocortical steroid hormones) pass into the bloodstream once synthesized without being stored in cells.

Feedback control mechanisms

Hormone secretion is controlled by the following feedback mechanisms: [2]

Diagnosis of endocrine diseases

Hypothalamus and pituitary glandtoggle arrow icon


Pituitary gland (hypophysis)

B-FLAT”: Basophils secrete FSH, LH, ACTH, and TSH.

PiG on Acid”: Prolactin and GH are secreted by Acidophils.

Hypothalamic-pituitary axistoggle arrow icon

Hypothalamus and anterior pituitary

Tropic hormones

Tropic hypothalamic hormones and their effects
Axis Hypothalamus Pituitary gland Endocrine target organ
Hypothalamic-pituitary-adrenal axis
  • CRH
    • Stimulates ACTH, MSH, and β-endorphin secretion from proopiomelanocortin (POMC) precursor
    • CRH levels decrease after long-term steroid treatment via negative feedback.
Hypothalamic-pituitary-thyroid axis
Hypothalamic-pituitary-gonadal axis
  • Gonadotropins
    • LH
    • FSH: stimulates the maturation of germ cells in both male and female individuals

Nontropic hormones

Nontropic hypothalamic hormones and their effects
Axis Hypothalamus Pituitary gland
Hypothalamic-pituitary-somatotropic axis
Hypothalamic-pituitary-prolactin axis
Hypothalamic-melanocortin system
  • Melanocyte-inhibiting hormone: inhibits release of MSH

“No PRO-BLAM:” Derivatives of PROopiomelanocortin are Beta-endorphin, ACTH, and MSH.

Hypothalamus and posterior pituitary

Hormones of the posterior pituitary gland
Hormone Regulation [9] Main effects Clinical relevance
Antidiuretic hormone
  • Involved in the neuromodulation of social and reproductive behavior, fear, anxiety, and depression

Hypothalamic and pituitary drugstoggle arrow icon

Overview of hypothalamic and pituitary drugs
Drug class Examples Mechanism of action Indications Side effects
GnRH agonists
GnRH antagonists
  • Degarelix
Somatostatin analogs
GHRH analogs [15]
  • Tesamorelin
GH receptor antagonists
  • Pegvisomant
Dopamine agonists

ADH antagonists [17][18]

ADH analogs
  • Desmopressin
  • Terlipressin
  • Mediates calcium influx → uterine contraction

Adrenal cortextoggle arrow icon

Thyroid glandtoggle arrow icon

Gonadstoggle arrow icon


Physiological effects of LH and FSH

Hormone Target gonad
Ovary Testicle

Physiological effects of sex hormones

Feedback control mechanisms

Regulation of appetite and satietytoggle arrow icon

Overview [22][23][24]

Regulation of appetite

Neuroendocrine regulation of appetite
Neurotransmitter/hormone Regulation Site of production Effects
Ghrelin [22][24]
  • Hunger [25]
  • Intake of fatty and sweet food
  • Unclear [26]
Neuropeptide Y
  • Hunger
  • ↑ Appetite
  • Regulation of anxiety-related behavior
  • Increased neuronal excitability

Regulation of satiety [22][24]

Neuroendocrine regulation of satiety
Hormone Regulation Source Effects
  • ↓ Appetite (short term)
  • ↓ Gastric emptying
Peptide YY
  • ↓ Appetite (short term)
  • ↓ Gastric emptying
Amylin [28]
  • Glucose (cosecreted with insulin)
  • ↓ Appetite (short term)
  • ↓ Gastric emptying
  • Glucagon release

Ghrelin makes you Gain weight. Leptin makes you Lose weight.

Appetite regulators

Appetite-regulating drugs
Drug class Example Mechanism of action Indication Side effects

Cannabinoid receptor agonist [29][30]

Synthetic progestin
  • Unclear [31]
GLP-1 agonist [34]

Referencestoggle arrow icon

  1. Robertson JF, Blamey RW.. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.. European Journal of Cancer. 2003.
  2. Tarlatzis BC. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006; 12 (4): p.333-340.doi: 10.1093/humupd/dml001 . | Open in Read by QxMD
  3. Souza FM, Collett-Solberg PF. Adverse effects of growth hormone replacement therapy in children. Arquivos Brasileiros de Endocrinologia & Metabologia. 2011; 55 (8): p.559-565.doi: 10.1590/s0004-27302011000800009 . | Open in Read by QxMD
  4. Gupta V, Lee M. Lee M. Growth hormone in chronic renal disease. Indian J Endocrinol Metab. 2012; 16 (2): p.195-203.doi: 10.4103/2230-8210.93736 . | Open in Read by QxMD
  5. Narayen G, Mandal S. Vasopressin receptor antagonists and their role in clinical medicine. Indian Journal of Endocrinology and Metabolism. 2012; 16 (2): p.183-191.doi: 10.4103/2230-8210.93734 . | Open in Read by QxMD
  6. Katzung BG. Basic and Clinical Pharmacology 14th Edition. McGraw Hill Professional ; 2017
  7. $SAMSCA® (tolvaptan) tablets, for oral use.
  8. Przybyla L, Voldman J. Probing Embryonic Stem Cell Autocrine and Paracrine Signaling Using Microfluidics. Annual Review of Analytical Chemistry. 2012; 5: p.293-315.doi: 10.1146/annurev-anchem-062011-143122 . | Open in Read by QxMD
  9. Prummel MF, Brokken LJS, Wiersinga WM. Ultra Short-Loop Feedback Control of Thyrotropin Secretion. Thyroid. 2004; 14 (10): p.825-829.doi: 10.1089/thy.2004.14.825 . | Open in Read by QxMD
  10. Standring S. Gray's Anatomy: The Anatomical Basis of Clinical Practice. Elsevier Health Sciences ; 2016
  11. Nussey S, Whitehead S. Endocrinology: An Integrated Approach. BIOS Scientific Publishers ; 2011
  12. Alhalabi M. Predictive value of serum Inhibin-B levels as an indicator of the presence of testicular spermatozoa in non-obstructive azoospermia. Middle East Fertility Society Journal. 2016; 21 (4): p.246-252.doi: 10.1016/j.mefs.2016.05.001 . | Open in Read by QxMD
  13. Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Practice & Research Clinical Endocrinology & Metabolism. 2009; 23 (6): p.793-800.doi: 10.1016/j.beem.2009.08.003 . | Open in Read by QxMD
  14. Murray PG, Clayton PE. Endocrine Control of Growth. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2013; 9999: p.1-10.doi: 10.1002/ajmg.c.31357 . | Open in Read by QxMD
  15. Mazziotti G, Giustina A. Glucocorticoids and the regulation of growth hormone secretion. Nature Reviews Endocrinology. 2013; 9 (5): p.265-276.doi: 10.1038/nrendo.2013.5 . | Open in Read by QxMD
  16. Cordido F, Peino R, et al. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.. The Journal of Clinical Endocrinology & Metabolism. 1996; 81 (3): p.914-918.doi: 10.1210/jcem.81.3.8772550 . | Open in Read by QxMD
  17. Kim JD, Leyva S, Diano S. Hormonal regulation of the hypothalamic melanocortin system. Frontiers in Physiology. 2014; 5.doi: 10.3389/fphys.2014.00480 . | Open in Read by QxMD
  18. Vasopressin (Antidiuretic Hormone). Updated: August 12, 2016. Accessed: August 18, 2020.
  19. Cuzzo B, Padala SA, Lappin SL. Vasopressin (Antidiuretic Hormone, ADH). StatPearls [Internet]. 2020.
  20. Buford L, Nichols Jr. The role of antidiuretic hormone in corticotrophin release.. Yale J Biol Med. 1961; 33 (6): p.415-434.
  21. Hobson RM, Maughan RJ. Hydration Status and the Diuretic Action of a Small Dose of Alcohol. Alcohol and Alcoholism. 2010; 45 (4): p.366-373.doi: 10.1093/alcalc/agq029 . | Open in Read by QxMD
  22. Posovszky C, Wabitsch M. Regulation of Appetite, Satiation, and Body Weight by Enteroendocrine Cells. Part 1: Characteristics of Enteroendocrine Cells and Their Capability of Weight Regulation. Hormone Research in Paediatrics. 2015; 83 (1): p.1-10.doi: 10.1159/000368898 . | Open in Read by QxMD
  23. Posovszky C, Wabitsch M. Regulation of Appetite, Satiation, and Body Weight by Enteroendocrine Cells. Part 2: Therapeutic Potential of Enteroendocrine Cells in the Treatment of Obesity. Hormone Research in Paediatrics. 2015; 83 (1): p.11-18.doi: 10.1159/000369555 . | Open in Read by QxMD
  24. Hall J, Roberts R, Vora N. Energy Homoeostasis: The Roles of Adipose Tissue-Derived Hormones, Peptide YY and Ghrelin. Obesity Facts. 2009; 2 (2): p.117-125.doi: 10.1159/000208517 . | Open in Read by QxMD
  25. DiPatrizio NV. Endocannabinoids in the Gut. Cannabis and Cannabinoid Research. 2016; 1 (1): p.67-77.doi: 10.1089/can.2016.0001 . | Open in Read by QxMD
  26. Hillard CJ. Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?. Neuropsychopharmacology. 2017; 43: p.155-172.doi: 10.1038/npp.2017.130 . | Open in Read by QxMD
  27. Di Marzo V, Ligresti A, Cristino L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes. 2009; 33: p.S18-S24.doi: 10.1038/ijo.2009.67 . | Open in Read by QxMD
  28. Roth JD. Amylin and the regulation of appetite and adiposity. Current Opinion in Endocrinology & Diabetes and Obesity. 2013; 20 (1): p.8-13.doi: 10.1097/med.0b013e32835b896f . | Open in Read by QxMD
  29. Katzung BG, Trevor AJ. Basic and Clinical Pharmacology 14E. McGraw-Hill Education / Medical ; 2017
  30. Pertwee RG. Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philosophical Transactions of the Royal Society B: Biological Sciences. 2012; 367 (1607): p.3353-3363.doi: 10.1098/rstb.2011.0381 . | Open in Read by QxMD
  31. Yeh S, Schuster MW. Megestrol acetate in cachexia and anorexia. Int J Nanomedicine. 2006; 1 (4): p.411-416.doi: 10.2147/nano.2006.1.4.411 . | Open in Read by QxMD
  32. Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, Gonzalvez Perales JL, Bort-Martí S. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews. 2013; 3.doi: 10.1002/14651858.cd004310.pub3 . | Open in Read by QxMD
  33. Mann M. Glucocorticoidlike Activity of Megestrol. Arch Intern Med. 1997; 157 (15): p.1651-1656.doi: 10.1001/archinte.1997.00440360053005 . | Open in Read by QxMD
  34. Gillani SM, Singh BM. The use of GLP-1 agonist therapy, liraglutide, is associated with significant weight loss in morbidly obese people without diabetes. British Journal of Diabetes. 2015; 15 (2): p.61-64.doi: 10.15277/bjdvd.2015.011 . | Open in Read by QxMD
  35. Abdel-Rahman MY. Androgen Excess Workup. In: Lucidi RS, Androgen Excess Workup. New York, NY: WebMD. Updated: August 1, 2016. Accessed: February 12, 2017.
  36. Cordera F, Grant C, Van Heerden J, Thompson G, Young W. Androgen-secreting adrenal tumors. Surgery. 2003; 134 (6): p.874-80.doi: 10.1016/S0039 . | Open in Read by QxMD
  37. Katzung B,Trevor A. Basic and Clinical Pharmacology. McGraw-Hill Education ; 2014
  38. Rosol TJ, Yarrington JT, Latendresse J, Capen CC. Adrenal Gland: Structure, Function, and Mechanisms of Toxicity. Toxicol Pathol. 2001; 29 (1): p.41-48.doi: 10.1080/019262301301418847 . | Open in Read by QxMD

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer